Evaluation of a Combination of Cystine, B Vitamins and Minerals, in the Management of Diffuse Hair Loss in Women: A Prospective, Open-Label Study

Objectives: This prospective, open‑label, non‑randomized study evaluated a specific combination of cystine, B vitamins, and minerals (Pantovigar^® vegan) in 34 women (aged 30-75 years) with diffuse hair loss (Modified Savin Score 1–3) for improvements in hair condition and product acceptance and safety following up to 6 months of intake of one test product capsule three times daily. Methods: Hair condition was assessed using phototrichogram analysis, and participants completed a product acceptance questionnaire. Blood nutrient levels associated with hair loss were measured at baseline, and at 3 and 6 months. Results: From baseline to 6 months, a significant increase of 2.35% in the rate of anagen (p = 0.012) and a decrease of 2.35% in the rate of telogen (p = 0.012) hairs resulted in an increase of 2.37% in the ratio of anagen/telogen hair rate (p = 0.013), reflecting a proportionate increase in the number of terminal hairs in the anagen phase. Most participants agreed with positive questionnaire hair condition statements. Increased levels of B vitamins, ferritin, and hematocrit did not exceed established tolerable upper limits, and no serious undesired effects were reported. Conclusion: The study results suggested that the specific nutrient combination of cystine, B vitamins, and minerals in the test product is beneficial to hair condition, is well‑accepted, and safe for use in the management of diffuse hair loss in women. Clinical Trial Registration: [https://clinicaltrials.gov/study/NCT05943860]; identifier [NCT05943860]; date of registration: June 21, 2023; retrospectively registered.